CONTEXT THERAPEUT.DL-,001CC

CONTEXT THERAPEUT.DL-,001

0.740EURD
−0.035−4.52%
As of today at 07:12 GMT
EUR
No trades
See on Supercharts
Next report date
March 19
Report period
Q4 2024
EPS estimate
−0.09 EUR
Revenue estimate
0.00 EUR
Market capitalization
‪61.31 M‬EUR
−0.820EUR
‪−21.71 M‬EUR
0.00EUR
‪43.75 M‬
Beta (1Y)
0.39
Employees (FY)
5
Change (1Y)
−4 −44.44%
Revenue / Employee (1Y)
Net income / Employee (1Y)

About Context Therapeutics Inc.


CEO
Martin A. Lehr
Headquarters
Philadelphia
Founded
2015
FIGI
BBG013TG0H70
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.
Performance
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−16.00 M‬‬
‪‪−12.00 M‬‬
‪‪−8.00 M‬‬
‪‪−4.00 M‬‬
‪0.00‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−18.00 M‬‬
‪‪−13.50 M‬‬
‪‪−9.00 M‬‬
‪‪−4.50 M‬‬
‪0.00‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−16.00 M‬‬
‪‪−12.00 M‬‬
‪‪−8.00 M‬‬
‪‪−4.00 M‬‬
‪0.00‬
Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−35.00 M‬‬
‪0.00‬
‪‪35.00 M‬‬
‪‪70.00 M‬‬
‪‪105.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Earnings
Next:Mar 19, 2025
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪−0.44‬
‪−0.33‬
‪−0.22‬
‪−0.11‬
‪0.00‬
Actual
Estimate

No news here

Looks like there's nothing to report right now

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange CONTEXT THERAPEUT.DL-,001 stocks are traded under the ticker 6K9.
We've gathered analysts' opinions on CONTEXT THERAPEUT.DL-,001 future price: according to them, 6K9 price has a max estimate of 9.59 EUR and a min estimate of 3.84 EUR. Watch 6K9 chart and read a more detailed CONTEXT THERAPEUT.DL-,001 stock forecast: see what analysts think of CONTEXT THERAPEUT.DL-,001 and suggest that you do with its stocks.
6K9 reached its all-time high on Dec 1, 2021 with the price of 8.985 EUR, and its all-time low was 0.420 EUR and was reached on May 5, 2023. View more price dynamics on 6K9 chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track CONTEXT THERAPEUT.DL-,001 financials in yearly and quarterly reports right on TradingView.
CONTEXT THERAPEUT.DL-,001 is going to release the next earnings report on Mar 19, 2025. Keep track of upcoming events with our Earnings Calendar.
6K9 earnings for the last quarter are −0.20 EUR per share, whereas the estimation was −0.08 EUR resulting in a −144.44% surprise. The estimated earnings for the next quarter are −0.09 EUR per share. See more details about CONTEXT THERAPEUT.DL-,001 earnings.
CONTEXT THERAPEUT.DL-,001 revenue for the last quarter amounts to 0.00 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
6K9 net income for the last quarter is ‪−15.68 M‬ EUR, while the quarter before that showed ‪−2.10 M‬ EUR of net income which accounts for −645.03% change. Track more CONTEXT THERAPEUT.DL-,001 financial stats to get the full picture.
No, 6K9 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 28, 2025, the company has 5.00 employees. See our rating of the largest employees — is CONTEXT THERAPEUT.DL-,001 on this list?
Like other stocks, 6K9 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CONTEXT THERAPEUT.DL-,001 stock right from TradingView charts — choose your broker and connect to your account.